Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C24H23N3O2 |
| Molecular Weight | 385.4583 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C1NC2=CC=CC(N3CCN(CC4=CC=CC(=C4)C5=CC=CC=C5)CC3)=C2O1
InChI
InChIKey=CYGODHVAJQTCBG-UHFFFAOYSA-N
InChI=1S/C24H23N3O2/c28-24-25-21-10-5-11-22(23(21)29-24)27-14-12-26(13-15-27)17-18-6-4-9-20(16-18)19-7-2-1-3-8-19/h1-11,16H,12-15,17H2,(H,25,28)
Bifeprunox, code name DU-127,090 is an atypical antipsychotic agent, which combines minimal D2 receptor agonism with 5-HT receptor agonism. Bifeprunox was in phase III of clinical trials for the treatment of schizophrenia, Bipolar Depression and in phase I for Parkinson's disease, but these studies were discontinued because efficacy data did not support pursuing the existing development strategy of stabilization of non-acute patients with schizophrenia.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL214 |
8.0 null [pKi] | ||
Target ID: P14416 Gene ID: 1813.0 Gene Symbol: DRD2 Target Organism: Homo sapiens (Human) |
8.5 null [pKi] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
381.5 ng × h/mL |
20 mg 1 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
BIFEPRUNOX plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
825.1 ng × h/mL |
40 mg 1 times / day multiple, oral dose: 40 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
BIFEPRUNOX plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1% |
20 mg 1 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
BIFEPRUNOX plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
1% |
40 mg 1 times / day multiple, oral dose: 40 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
BIFEPRUNOX plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| New 1-aryl-4-(biarylmethylene)piperazines as potential atypical antipsychotics sharing dopamine D(2)-receptor and serotonin 5-HT(1A)-receptor affinities. | 2001 Sep 3 |
|
| Aripiprazole: the evidence of its therapeutic impact in schizophrenia. | 2006 |
|
| Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase. | 2006 Mar 18 |
|
| Drug-drug interactions associated with second-generation antipsychotics: considerations for clinicians and patients. | 2007 |
|
| Differences in agonist/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208-912. | 2007 Nov 28 |
|
| Pharmacological causes of hyperprolactinemia. | 2007 Oct |
|
| Differential profile of typical, atypical and third generation antipsychotics at human 5-HT7a receptors coupled to adenylyl cyclase: detection of agonist and inverse agonist properties. | 2007 Oct |
|
| Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability. | 2008 |
|
| Bipolar depression: trial-based insights to guide patient care. | 2008 |
|
| Dopamine D2(High) receptors moderately elevated by bifeprunox and aripiprazole. | 2008 Dec |
|
| Antipsychotics differ in their ability to internalise human dopamine D2S and human serotonin 5-HT1A receptors in HEK293 cells. | 2008 Feb 26 |
|
| Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. | 2008 Jan |
|
| Actions of novel agonists, antagonists and antipsychotic agents at recombinant rat 5-HT6 receptors: a comparative study of coupling to G alpha s. | 2008 Jul 7 |
|
| Effects of antipsychotics and reference monoaminergic ligands on marble burying behavior in mice. | 2008 Mar |
|
| Agonist and antagonist properties of antipsychotics at human dopamine D4.4 receptors: G-protein activation and K+ channel modulation in transfected cells. | 2008 May |
|
| Serotonergic approaches in the development of novel antipsychotics. | 2008 Nov |
|
| Bifeprunox and aripiprazole suppress in vivo VTA dopaminergic neuronal activity via D2 and not D3 dopamine autoreceptor activation. | 2009 Aug 21 |
|
| Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour. | 2009 Mar |
|
| Differences among conventional, atypical and novel putative D(2)/5-HT(1A) antipsychotics on catalepsy-associated behaviour in cynomolgus monkeys. | 2009 Nov 5 |
|
| The effect of metformin on anthropometrics and insulin resistance in patients receiving atypical antipsychotic agents: a meta-analysis. | 2010 Oct |
|
| Not all partial dopamine D(2) receptor agonists are the same in treating schizophrenia. Exploring the effects of bifeprunox and aripiprazole using a computer model of a primate striatal dopaminergic synapse. | 2010 Sep 7 |
|
| Identification of N-propylnoraporphin-11-yl 5-(1,2-dithiolan-3-yl)pentanoate as a new anti-Parkinson's agent possessing a dopamine D2 and serotonin 5-HT1A dual-agonist profile. | 2011 Jul 14 |
Patents
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29710
Created by
admin on Fri Dec 15 16:38:33 GMT 2023 , Edited by admin on Fri Dec 15 16:38:33 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
AP69E83Z79
Created by
admin on Fri Dec 15 16:38:33 GMT 2023 , Edited by admin on Fri Dec 15 16:38:33 GMT 2023
|
PRIMARY | |||
|
C65262
Created by
admin on Fri Dec 15 16:38:33 GMT 2023 , Edited by admin on Fri Dec 15 16:38:33 GMT 2023
|
PRIMARY | |||
|
8266
Created by
admin on Fri Dec 15 16:38:33 GMT 2023 , Edited by admin on Fri Dec 15 16:38:33 GMT 2023
|
PRIMARY | |||
|
100000089783
Created by
admin on Fri Dec 15 16:38:33 GMT 2023 , Edited by admin on Fri Dec 15 16:38:33 GMT 2023
|
PRIMARY | |||
|
CHEMBL218166
Created by
admin on Fri Dec 15 16:38:33 GMT 2023 , Edited by admin on Fri Dec 15 16:38:33 GMT 2023
|
PRIMARY | |||
|
SUB20312
Created by
admin on Fri Dec 15 16:38:33 GMT 2023 , Edited by admin on Fri Dec 15 16:38:33 GMT 2023
|
PRIMARY | |||
|
C509981
Created by
admin on Fri Dec 15 16:38:33 GMT 2023 , Edited by admin on Fri Dec 15 16:38:33 GMT 2023
|
PRIMARY | |||
|
BIFEPRUNOX
Created by
admin on Fri Dec 15 16:38:33 GMT 2023 , Edited by admin on Fri Dec 15 16:38:33 GMT 2023
|
PRIMARY | |||
|
m2484
Created by
admin on Fri Dec 15 16:38:33 GMT 2023 , Edited by admin on Fri Dec 15 16:38:33 GMT 2023
|
PRIMARY | Merck Index | ||
|
DB04888
Created by
admin on Fri Dec 15 16:38:33 GMT 2023 , Edited by admin on Fri Dec 15 16:38:33 GMT 2023
|
PRIMARY | |||
|
350992-10-8
Created by
admin on Fri Dec 15 16:38:33 GMT 2023 , Edited by admin on Fri Dec 15 16:38:33 GMT 2023
|
PRIMARY | |||
|
208951
Created by
admin on Fri Dec 15 16:38:33 GMT 2023 , Edited by admin on Fri Dec 15 16:38:33 GMT 2023
|
PRIMARY | |||
|
DTXSID80188592
Created by
admin on Fri Dec 15 16:38:33 GMT 2023 , Edited by admin on Fri Dec 15 16:38:33 GMT 2023
|
PRIMARY | |||
|
RR-138
Created by
admin on Fri Dec 15 16:38:33 GMT 2023 , Edited by admin on Fri Dec 15 16:38:33 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
